Patent settlements between originator and generic firms in the pharmaceutical industry have been challenged by antitrust and competition authorities in the U.S. and the EU. Particularly settlements with large "reverse payments" to generic firms raise the concern of collusive behaviour for...

Comparative analysis of the industrial concentration and turnover of the pharmaceutical industry in Brazil for the segments of mark and generic drugs - This paper analyzes the evolution of brand-name and generic drugs structure in Brazil since 1997. After the introduction of generic drugs it was...

With the expiry of the Pharmaceutical Industry Investment Program (PIIP) in 2004, the Commission was asked to conduct an evaluation of the program’s rationale, effectiveness and efficiency. The study commenced in August 2002. The Commission found that this assistance scheme had significant...